The current study investigates the expression of cytotoxicity-related receptors (CD16, CD56, CD57, CD69) and a checkpoint (LAG-3) on γδ T cells in CLL patients. The gene discussed is NCAM1; the disease is B-cell chronic lymphocytic leukemia.